OMEICOS Therapeutics GmbH - News

Talk by Robert Fischer, MD at 40th ANNUAL HEART RHYTHM SCIENTIFIC SESSIONS 2019 in San Francisco

Heart Rhythm 2019 will be held May 8-11, 2019 in San Francisco, CA and will convene the finest clinicians, scientists, researchers, and innovators in the field of cardiac pacing and electrophysiology. More than 800 of the world’s most noted experts in cardiac rhythm management will serve as faculty for more than 200 educational sessions covering topic areas such as pacing, defibrillation, clinical arrhythmia management, ablation, pharmacology, genetics, basic science, health policy, and more.

Presenting Author: Robert Fischer, MD
Presentation Title: Development Of Omt-28, A Small Molecule Targeting Intracellular Ca2+-handling And Mitochondrial Function, For Rhythm Control In Atrial Fibrillation Patients: Scientific Rationale And Study Design
Presentation Time: 5/9/2019 9:00:00 AM – 5/9/2019 9:15:00 AM
Abstract Session Title: What's New in Atrial Fibrillation: New Methodologies, New Players, and New Therapies

OMEICOS Therapeutics Strengthens Board of Directors with the Appointment of Christian Schetter

-- Addition of 2nd independent board member positions OMEICOS well for future value creation --

Berlin, Germany, and Boston, MA, USA, February 11, 2019 – OMEICOS Therapeutics, a biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of Christian Schetter, Ph.D., as an independent Board Member.

OMEICOS Therapeutics Closes €17m Series C Financing to Advance Lead Candidate OMT-28 Towards Pivotal Trials in Atrial Fibrillation

Proceeds provide OMEICOS with the financial runway to conduct the Phase II Study PROMISE-AF and continue expansion into ophthalmology through US subsidiary

Berlin, Germany, and Boston, MA, USA, November 2, 2018 – OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the closing of a EUR 17 million (approx. USD 19.5 million) Series C financing led by new investor Forbion.

OMEICOS Therapeutics Announces Compelling First-in-Human Data on Lead Compound OMT-28 and Prepares Phase 2 Trial in Atrial Fibrillation

High-resolution electrocardiography strongly supports OMT-28’s claim for low pro-arrhythmic risk

Berlin, Germany, July,17 2018 – OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced results from its first-in-human clinical study for OMT-28.

Alexander Gebauer Joins Executive Board of OMEICOS Therapeutics and Named CEO and Chairman of OMEICOS Ophthalmics

Appointment marks further progress in ramping-up US-based subsidiary as validation of OMEICOS’ lead compound also progresses through clinical trials in atrial fibrillation

Berlin, Germany, and Boston, MA, USA, April 27, 2018 – OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of Alexander Gebauer, MD, Ph.D., to the Company’s Management Board.

OMEICOS Announces Formation of Inaugural Clinical Advisory Board

Leading Experts in Atrial Fibrillation to Complement the Company’s Key Focus Area

Berlin, Germany, November 13, 2017 — OMEICOS Therapeutics, a Berlin-based biopharmaceutical company developing first-in-class small molecule therapeutics for the prevention and treatment of cardiovascular and ophthalmic diseases, today announced the appointment of leading experts in the field of cardiac arrhythmias to the company’s Clinical Advisory Board (CAB). The multinational group of specialists will serve as a strategic resource to OMEICOS as it continues to advance its lead compound, OMT-28, currently in a Phase I clinical trial. The CAB will provide counsel to the company as OMEICOS starts to design a Phase II program for maintenance of sinus rhythm in patients with atrial fibrillation.